** Shares of Alphamab Oncology 9966.HK drop 11.8% to HK$8.07, their biggest intraday pct decline since May 12
** Stock hits the lowest since May 21, and on course to snap three straight sessions of gains, if current trend holds
** Alphamab Oncology says controlling shareholder plans to sell 14.6 mln existing shares at HK$8.05 each in share placement, reducing its stake to 31% from 32.5%
** Co says the controlling shareholder will use the proceeds to repay existing personal liabilities and debts, and the placement is not expected to have any impact on its business or operations
** The Hang Seng Biotech Index .HSHKBIO gains 1.3% and the Hang Seng Index .HSI climbs 1.2%
** Alphamab stock up 133.7%, YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。